Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Acorda

This page shows the latest Acorda news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

There were two other positive opinions on new medicines at the CHMP meeting last week, with the panel backing Acorda Therapeutics’ inhaled Inbrija (levodopa) for the treatment of symptoms of ‘off’

Latest news

  • Biotech leaders jump into US free speech debate Biotech leaders jump into US free speech debate

    Alnylam chief executive John Maraganore, Decibel Therapeutics’ CEO Steve Holtzman, Acorda CEO Ron Cohen and Jeremy Levin of Ovid Therapeutics are the main signatories to the letter published In Nature, but

  • Biogen pays $590m for Pfizer cognition drug Biogen pays $590m for Pfizer cognition drug

    The biotech company has also been linked to a possible takeover offer for Acorda Therapeutics and its Parkinson’s diseases candidates Inbrija (inhaled levodopa) and SYN-201.

  • Acorda acquires Biotie to expand in Parkinson's disease Acorda acquires Biotie to expand in Parkinson's disease

    Strikes $363m deal for Finnish firm. Acorda Therapeutics has agreed to buy Finland's Biotie Therapies in a $363m deal that swells its pipeline of Parkinson's disease (PD) drug candidates. ... The deal will also give Acorda four phase III programmes that -

  • Multiplying options for MS

    Acorda and Biogen Idec's Ampyra (fampridine sustained-release), a potassium channel antagonist that has been shown to restore conduction in demyelinated axons in patients with MS, was approved in the

  • A competitive edge

    Philippines. Dalfampridine . Ampyra (Acorda Therapeutics). Multiple sclerosis. USA, Puerto Rico. Desirudin .

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Dr Catherine Strader joins Acorda Therapeutics’ board Dr Catherine Strader joins Acorda Therapeutics’ board

    Acorda Therapeutics has expanded its board of directors with the addition of Dr Catherine Strader. ... Dr Ron Cohen, Acorda's president and chief executive officer, said: “Catherine brings decades of experience as both a drug developer and

  • Acorda Therapeutics appoints chief medical officer Acorda Therapeutics appoints chief medical officer

    New York-based biotech Acorda Therapeutics has appointed Dr Burkhard Blank as its chief medical officer. ... Burkhard brings to Acorda an impressive record of successful drug development and approved NDAs.

  • Acorda appoints new CFO Acorda appoints new CFO

    Michael Rodgers replaces David Lawrence who becomes chief business officer. Acorda has reshuffled its senior business leadership, with Michael Rodgers appointed chief financial officer replacing David Lawrence who becomes chief business ... I'm excited

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Wallace Health

Wallace Health is a healthcare and medical content agency with a successful track record of delivering web content, content marketing...

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...

Quick links